- Home
- LWAY vs XNCR Comparison
LWAY vs XNCR Comparison
Compare LWAY & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWAY
- XNCR
- Stock Information
- Founded
- LWAY 1986
- XNCR 1997
- Country
- LWAY United States
- XNCR United States
- Employees
- LWAY N/A
- XNCR N/A
- Industry
- LWAY Packaged Foods
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- LWAY Consumer Staples
- XNCR Health Care
- Exchange
- LWAY Nasdaq
- XNCR Nasdaq
- Market Cap
- LWAY 464.0M
- XNCR 547.8M
- IPO Year
- LWAY 1987
- XNCR 2013
- Fundamental
- Price
- LWAY $33.72
- XNCR $8.49
- Analyst Decision
- LWAY Buy
- XNCR Buy
- Analyst Count
- LWAY 2
- XNCR 10
- Target Price
- LWAY $33.00
- XNCR $23.33
- AVG Volume (30 Days)
- LWAY 68.6K
- XNCR 718.3K
- Earning Date
- LWAY 11-13-2025
- XNCR 11-05-2025
- Dividend Yield
- LWAY N/A
- XNCR N/A
- EPS Growth
- LWAY N/A
- XNCR N/A
- EPS
- LWAY 0.70
- XNCR N/A
- Revenue
- LWAY $193,021,000.00
- XNCR $146,929,000.00
- Revenue This Year
- LWAY $14.66
- XNCR $22.06
- Revenue Next Year
- LWAY $13.81
- XNCR N/A
- P/E Ratio
- LWAY $47.50
- XNCR N/A
- Revenue Growth
- LWAY 9.19
- XNCR N/A
- 52 Week Low
- LWAY $19.50
- XNCR $6.92
- 52 Week High
- LWAY $33.61
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- LWAY 73.13
- XNCR 55.28
- Support Level
- LWAY $28.55
- XNCR $8.26
- Resistance Level
- LWAY $32.85
- XNCR $8.73
- Average True Range (ATR)
- LWAY 1.19
- XNCR 0.38
- MACD
- LWAY 0.13
- XNCR 0.06
- Stochastic Oscillator
- LWAY 98.48
- XNCR 69.03
About LWAY Lifeway Foods Inc.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.